New! Sign up for our free email newsletter.

Lymphoma News

June 13, 2025

Top Headlines

 

A team identified herpes virus saimiri, which infects the T cells of squirrel monkeys, as a source of proteins that activate pathways in T cells that are needed to promote T cell ...
Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form ...
A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory ...
Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat ...
A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy ...
Research has shown that tattoo ink does not just remain where it is injected. Particles from the ink can migrate to the lymph nodes, where they ...
Researchers have discovered and analysed a rare but serious side effect of an innovative form of blood cancer ...
A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells fight cancer more effectively. These findings ...
A look at cancer cells: Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their destruction. Their research ...
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer ...

Latest Headlines

updated 11:47am EDT

Earlier Headlines

 

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...

In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large study now finds the risk is low and not related to the CAR-T ...

CAR-T cell therapies are transforming the treatment of previously incurable blood cancers, but a large proportion of patients still responds only poorly or not at all to them, calling for new ...

A new study from Sweden suggests that tattoos could be a risk factor for cancer in the lymphatic system, or lymphoma. Now, the researchers underline the need for more research on the ...

The Epstein-Barr virus can cause a spectrum of diseases, including a range of cancers. Emerging data now show that inhibition of a specific metabolic pathway in infected cells can diminish latent ...

A recently completed study indicates that circulatory protein levels can provide important information for increasingly accurate diagnoses and personalised care in patients with aggressive B-cell ...

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments ...

Researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer. The research points to effective ...

Scientists may have found a way around the limitations of engineered T cells by borrowing a few tricks from cancer itself. By studying mutations in malignant T cells that cause lymphoma, they zeroed ...

Researchers describe how specific gene activity could potentially enhance immune cell production. The researchers wanted to understand the mechanism of why some hematopoietic stem cells produce more ...

Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells. The ZUMA-7 trial demonstrated that axi-cel reduced the risk of disease progression, the need for new therapy, or death by 60% ...

Researchers have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of ...

Circulating tumor DNA predicts recurrence and splits disease into two subgroups of Hodgkin lymphoma. New drug targets or changes in treatments may reduce ...

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose ...

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

Men who are overweight or obese at age 18 have a higher risk of 17 different cancers later in life. This has been shown in a study at the University of Gothenburg. The research also describes how the ...

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of ...

Scientists have discovered a mechanism that linked a leukemic mutation to varying potentials for disease development -- a discovery which could eventually lead to a way to identify patients with the ...

A new substance has proven useful for treating staphylococcus infections in people with skin lymphoma. This is good news for the patients, but also for the global threat of antibiotics ...

The most comprehensive study to date of the blood cancer, Hodgkin lymphoma, has provided fascinating insights into what tumour cells must do to survive. Researchers found that cancer cells use ...

Friday, January 17, 2025

Wednesday, June 12, 2024

Friday, May 24, 2024

Thursday, May 23, 2024

Monday, April 29, 2024

Tuesday, March 12, 2024

Friday, March 1, 2024

Wednesday, February 7, 2024

Friday, January 26, 2024

Wednesday, January 17, 2024

Saturday, January 13, 2024

Monday, December 11, 2023

Sunday, December 10, 2023

Thursday, November 16, 2023

Monday, November 6, 2023

Thursday, July 27, 2023

Thursday, March 23, 2023

Friday, March 17, 2023

Monday, February 13, 2023

Tuesday, January 24, 2023

Monday, January 9, 2023

Thursday, December 22, 2022

Tuesday, November 22, 2022

Thursday, October 27, 2022

Thursday, September 8, 2022

Wednesday, August 24, 2022

Thursday, July 14, 2022

Tuesday, June 28, 2022